INTRODUCTION
Clinical multi-drug resistance (MDR) is frequently associated in tumors with expression of ATP-binding cassette (ABC) transporter proteins that actively efflux a variety of drugs to reduce intracellular drug concentrations (for review, 1). For example, in acute myeloid leukemia (AML), the ABC transporter, P-glycoprotein (Pgp), is commonly expressed at high levels in elderly AML patients and in patients with secondary AMLs. Several Pgp substrate drugs, including daunomycin (DNR), mitoxantrone (MIT), and etoposide (VP-16), are used in standard AML therapies, and Pgp expression is independently associated with lower complete remission (CR) rates and shorter remission durations (2, 3) . Related proteins of the ABC transporter family, including the multidrug resistance protein (MRP) and the breast cancer resistance protein (BCRP), are also expressed in AML and have been associated with MDR and poor clinical outcomes (4, 5) . Consequently, MDR modulators are being clinically tested in AML. For example, a phase III Southwest Oncology Group trial tested infusional cyclosporine A (CSA) with cytarabine plus DNR (6) . CSA significantly reduced refractory disease and improved overall and relapse-free survival, but only clearly benefited patients with Pgp-expressing leukemias. Other clinical studies of Pgp inhibitors have been less encouraging, particularly because CSA and similarly-acting agents often increased regimen-related toxicities, necessitating drug dose reductions (for reviews, 7, 8).
CSA not only efficiently inhibits Pgp-mediated efflux, but also weakly inhibits MRPmediated and BCRP-mediated transport (9-11), as does the investigational agent, VX-710 (Biricodar concentrations that were effective in these pre-clinical studies have been safely achieved in patients (22).
We have now addressed the mechanism by which PK11195 blocks efflux. First, we asked how broadly PK11195 blocks efflux and chemosensitizes hematologic cancer cells.
Second, we asked whether PK11195's efflux-blocking activities involve pBR interactions. We show herein that non-toxic doses of PK11195 block efflux in Pgp-expressing, MRPexpressing and BCRP-expressing leukemia and multiple myeloma (MM) cell lines, and primary AML cells. PK11195 broadly increases the cytotoxicity of the efflux substrate, mitoxantrone (MIT), as we previously showed for DNR and Mylotarg. PK11195 is apparently not an efflux substrate, but modulates Pgp-mediated efflux by a pBR-independent mechanism that involves direct interaction with a Pgp site(s) to which CSA does not bind.
Distinct from its efflux-blocking activity, PK11195 increases MIT-induced apoptosis by an efflux-independent mechanism that is enhanced by pBR overexpression. Since PK11195 can chemosensitize cancer cells that are abnormally dependent on one or more of these common drug resistance mechanisms, it may be an effective MDR modulator in cancer patients who would not benefit from CSA-based regimens, for example. Our data warrant additional pre-clinical studies and clinical tests of PK11195 as a chemosensitizer.
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MATERIALS AND METHODS
Chemical Reagents: All reagents were purchased from Sigma (St. Louis, MO), except Cytogenetic data are based on centrally-reviewed studies by SWOG-approved labs.
Cell Culture: Cell lines were obtained from the American Type Culture Collection, except RPMI-8226-derived MM and HL60-derived AML cell lines that were provided by Drs.
W. Dalton and K.N. Bhalla (both of the University of South Florida, Tampa, FL). Jurkat and KG1a derivatives were generated as described below. Stable BCRP-expressing ML1 and HL60 sublines and GFP control lines were previously produced by lentiviral transduction (23).
Cells were cultured in RPMI 1640 supplemented with 5% heat-inactivated bovine calf serum (BCS; Hyclone, Logan UT), except for HL60 cells that were cultured in Iscove's Modified Dulbecco's Medium (Gibco/Invitrogen, Carlsbad, CA) supplemented with 10% cosmic calf serum (Hyclone).
Efflux Assays: MIT is a fluorescent substrate for Pgp, MRP, and BCRP (24). Cells were incubated in MIT (20µM, 60min, 37°C) in the presence or absence of CSA (1µM), MK-571 (30) , and Pgp function was measured as DiOC 2 (3) (40nM) efflux inhibited by CSA (2) or as Hoechst, rhodamine 123 (5µg/ml), or Bodipy-prazosin (100nM) efflux (31, 32) after exposures without inhibitor (30min, 37°C) and release +/-inhibitor (30min, 37°C). Data were collected on a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA, USA) and analyzed with Multiplus software (Phoenix Flow Systems, San Diego, CA). All assays were repeated at least three times and expressed as mean ratios (mean fluorescence intensity (MFI) in the presence of inhibitor ÷ MFI in the absence of inhibitor) +/-standard errors of the mean (SEM).
Chemosensitivity Assays: Parallel cell cultures were incubated with drugs at concentrations described in the text. Cytotoxicity was determined by flow cytometry after DiOC 6 (3) plus propidium iodide staining was performed, or by scintillation counting after 24 hours of pBR RNA Assays: RNAs were prepared using TRIzol, and oligo(dT)-primed cDNA was synthesized using Superscript II and manufacturer's recommended protocols (Invitrogen).
GAPDH polymerase chain reactions (PCRs) were performed with standard techniques, using 45 cycles (95˚C denaturation, 70˚C annealing, 72˚C extension), AmpliTaq Polymerase (Roche) and, intron-spanning primers (forward 5'GTCTTCACCACCATGGAGAAG3' and reverse 5'GCTTCACCACCTTCT-TGATGTCATC3') to confirm mRNA integrity. pBR PCRs were performed (forward 5'CTCCCCTGAACAGCAGCTGC3' and reverse 5'GCCAAGGCCCTGACAGACTAGC3' primers), PCR products were separated on 2% agarose gels, and extracted for reamplification and dideoxy-sequencing to confirm pBR identity (33 Statistics: Due to the relatively small sample numbers that were analyzed in the current studies, non-parametric analyses with two-tailed Mann-Whitney unpaired tests, Wilcoxon matched pairs tests, and Spearman rank correlations were calculated using Instat3 software (GraphPad, San Diego, CA). P<0.05 was considered statistically significant. PK11195 was not measurably toxic in Pgp-expressing 8226-DOX40 MM cells (DOX40), while CSA was toxic at doses above 1µM ( Figure 1A) . 25µM MK-571 (MRP modulator; 25) and 1µM GF120918 (BCRP modulator; 26) were also non-toxic (data not shown). Therefore, we used these doses in MIT efflux assays in which ratios greater than 1 represent efflux inhibition. 1µM CSA dosing blocked MIT efflux in DOX40 cells (Figure 1A) , consistent with our previous findings using DiOC 2 (3) as the Pgp substrate dye (18). Higher, toxic CSA doses were not more effective, but 75µM PK11195 was more effective than 1µM CSA (p<0.05). Moreover, parental 8226, ML1, and HL60 cells that do not overexpress any ABC transporter were also MIT-sensitized by PK11195 co-treatments, but to a smaller degree than were efflux-proficient derivative cells (data not shown), consistent with PK11195's established ability to overcome the protective effects of Bcl-2 family proteins (19-21).
PK11195 blocks MIT efflux in primary AML cells in association with relatively high levels
of specific PK11195 binding. To expand upon our cell line data, we performed efflux assays with primary AML cell samples. We previously reported (18) that PK11195 blocks efflux of the Pgp-selective dye, DiOC 2 (3). Upon further analysis of these data, we found that efflux blockade by PK11195 and CSA was correlated (R=0.78, p = 0.005), although PK11195 increased DiOC 2 (3) retention in three samples in which CSA had no effect ( Figure 3A ).
When we performed MIT efflux assays in other primary AML cell samples, we found that PK11195 and/or CSA measurably increased MIT retention in 12 of 13 samples. CSA and PK11195 effects were again significantly correlated (R=0.78, p = 0.001). Eight samples were of sufficient size to also test MK-571 and Ko143 as specific MRP and BCRP modulators, respectively (18, 21, 25, 27). We previously showed that these modulators identify MRPexpressing and BCRP-expressing AML samples, in concordance with immunostaining by ABC transporter-specific monoclonal antibodies (22, 24). In this study, four AML samples were determined to be BCRP-expressing samples since Ko143 measurably blocked MIT efflux in these (#158736, 155976, 163086, 157389); one sample also functionally expressed Pgp (#158736) since MIT retention was increased substantially more by PK11195 and CSA than by Ko143, and one sample (#155976) also expressed MRP since MK-571 was effective.
Four other samples apparently only expressed Pgp since only PK11195 and CSA blocked MIT efflux in these samples. PK11195 was substantially more effective than any other effluxblocking agent in three of eight samples (38%), including BCRP-expressing and MRPexpressing cells. Jurkat cells, we were unable to measure MIT efflux in isogenic J-GFP and J-pBR cells, using CSA, MK-571, and Ko143 as Pgp, MRP and BCRP efflux modulators, respectively. PK11195 also had no effect. Thus, pBR expression alone was not sufficient to convey measurable efflux capacity to leukemia cells.
To address the possibility that cells must co-express pBR and Pgp in order for pBR to affect efflux, we next used KG1a AML cells as transduction recipients. Like parental KG1a cells ( Figures 1B and 3C) , control GFP-transduced KG1a cells (K-GFP) bound relatively low levels of PK11195, expressed Pgp, and were efflux-competent ( Figure 4C ). KG1a cells stably expressing the pBR/GFP expression vector (K-pBR) showed substantially increased pBR expression, but neither PK11195 nor CSA had greater efflux-blocking effects in K-pBR cells than in K-GFP cells. Thus, pBR apparently does not directly mediate efflux.
To ask whether pBR expression is required for PK11195's efflux-blocking activity, we produced Jurkat cell derivatives that functionally overexpress Pgp (J-MDR) or BCRP (J-BCRP), as demonstrated in specific antibody-binding and efflux assays (Figure 5A , 5B). In 
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while CSA and Ko143 had no significant effect. Dye retention was not affected by any compound in parental Jurkat or control J-GFP cells. These data substantiate PK11195's Pgp-inhibiting and BCRP-inhibiting activities, and again show that non-toxic doses of PK11195 can block efflux more effectively than non-toxic doses of CSA. Together, data from ectopic protein expression models strongly suggest that pBR expression is not required for PK11195's efflux-blocking activities.
PK11195 binds Pgp at binding sites distinct from those bound by CSA. Since we had shown that Pgp-expressing MM and AML cell lines and primary AML cell samples also express pBR (Figures 3C and 4C) , we wondered whether PK11195 binding to more abundant and/or higher affinity mitochondrial pBR reduced our ability to measure Pgp- (Figures 1 and 3) , was blocked significantly more by PK11195 than by CSA (p< 0.005). These data again show (Figures 3 and 6) , RHO, Hoechst, and PRAZ (data not shown).
Therefore, our data suggested that PK11195 might be a non-substrate Pgp modulator.
Pgp inhibitors include "substrates" that bind Pgp at transport sites and translocate across the lipid bilayer in an ATP-dependent process, and "modulators" that bind Pgp at regulatory sites to affect substrate recognition and/or ATP hydrolysis (49) . Both transported and nontransported modulators can induce Pgp-associated ATPase activity (50) . Therefore, we assayed PK11195 effects on Pgp-associated ATPase activities to ask whether PK11195 directly impacts Pgp function. First, we used commercially-available Pgp-containing microsomes produced from MDR1-transfected insect cells. Using VPL as a positive control treatment (49), we found that non-toxic doses of CSA (1µM) and PK11195 (75µM) substantially increased Pgp-associated ATPase activity in this model ( Figure 7A) . Next, we produced microsomal (mitochondria plus PM) fractions from parental 8226 cells and Pgpexpressing DOX40 cells, and found that PK11195 and VPL substantially stimulated ATPase activity in DOX40 cells, but not in 8226 cells, and that CSA had no effect ( Figure 7B ).
Finally, we prepared PM fractions from DOX40 cells, and tested a wider dose range of CSA and PK11195. Once again, VPL substantially increased ATPase activity ( Figure 7C ). Nontoxic PK11195 doses (5 to 75µM) also stimulated ATPase activity, but a toxic dose of CSA 
DISCUSSION
We previously showed that PK11195 is relatively non-toxic as a single agent when used at doses that can be safely achieved in patients, but that it consistently chemosensitizes AML and MM cells, including cells expressing Pgp, MRP, and/or anti-apoptotic proteins (18, 21).
We now confirm these findings, in leukemia and MM cell lines and primary AML cells, and show that non-toxic PK11195 doses can also block BCRP-mediated efflux and reverse chemoresistance in cancer cells overexpressing any of these efflux proteins. As in cancer cells that are responsible for refractory disease and relapse, chemotherapy resistance is associated with the expression of various ABC transporters in normal hematopoietic stem cells (e.g. 40-42). Consistent with these findings, we found that PK11195, CSA, and Ko143 all block efflux in normal CD34 +
CD38
-progenitor cells, as in malignant cells. Nonetheless, PK11195 has no significant chemosensitizing effect in normal bone marrow cell samples in our previous study (18), and does not exacerbate regimen-related toxicities in xenograft studies, including our AML model (21) and a cholangiocarcinoma model (55) . Consistent with the idea that MDR modulators can be safely used in cancer patients, CSA did not prolong neutropenia in AML patients when added to a DNR plus cytarabine regimen, despite improving outcomes for patients with Pgp-expressing AMLs (6).
Like PK11195, CSA is a broad-spectrum efflux inhibitor (9-11, 43), but PK11195 is frequently more effective than CSA in efflux-competent hematologic cancer cells. PK11195 is also frequently more effective than the MRP-selective modulator, MK-571, or the BCRP modulators, GF120918 and Ko143 (25) (26) (27) (28) (29) . It remains unclear whether high-affinity, highly selective Pgp modulators might be clinically more useful than broadly effective MDR modulators, and agents of both types are being tested in chemotherapy regimens. For example, Zosuquidar is a potent and specific inhibitor of Pgp, with no measured effect on MRP or BCRP (13, 14), whereas Biricodar potently modulates Pgp, MRP, and BCRP (12).
However, neither of these agents has been reported to have any activity against antiapoptotic mechanisms of chemoresistance, and cancer cells commonly overexpress antiapoptotic proteins as well as ABC transporters. Therefore, PK11195 still offers advantages as a chemoresistance modulator in its ability to both broadly block drug efflux and promote apoptosis, if it is sufficiently bioavailable and does not produce unacceptable toxicities. Having confirmed PK11195's promotion of MIT-induced apoptosis by a pBR-dependent, mitochondrial mechanism, we were interested to find that AML and MM cell lines that express Bcl-2 family proteins are sensitized to MIT by PK11195 co-treatments, but that parental, efflux-deficient cells are chemosensitized to a smaller degree that efflux-competent derivatives. These data suggested to us that PK11195's apoptosis-promoting and effluxblocking chemosensitizing effects are distinct. In fact, we have now determined that To our knowledge, PK11195 is the first MDR modulator shown to both broadly modulate ABC transporter-related and inhibit mitochondrial pore-related chemoresistance mechanisms. Since drug resistance limits cures in many cancers and is commonly associated in cancer cells with over-expression of one or more drug transporter and one or more anti-apoptotic protein, PK11195 might be a uniquely effective adjunct to standard chemotherapies, useful in settings in which CSA and other agents that incapacitate only one
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MDR mechanism might be ineffective. Our data warrant additional pre-clinical studies and clinical tests of PK11195 as a chemosensitizer.
For and GF120918 (GF, 1µM) were used as Pgp-, MRP-, and BCRP-modulators, respectively, along with dose ranges of PK11195, in MIT efflux assays of 7 additional AML and MM cell lines, 75µM PK11195 blocked MIT efflux significantly more than CSA in all cell lines tested, and blocked MIT efflux significantly more than GF in BCRP-transduced HL60 cells. In all cases, efflux rations were calculated as described in (A), and summary data from at least 3 assays are shown as means±SEM. 
